Comparing real world evidence to phase III data on apalutamide for nmCRPC
Prof Heather Payne and Prof Stéphane Oudard
Comparing real world evidence to phase III data on apalutamide for nmCRPC ( Prof Heather Payne and Prof Stéphane Oudard )
19 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for September 6-13, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
14 Sep 2020
Future directions of PARP inhibitors in prostate cancer
Dr Jacob Adashek - The University of South Florida, Tampa, USA
Future directions of PARP inhibitors in prostate cancer ( Dr Jacob Adashek -  The University of South Florida, Tampa, USA )
10 Sep 2020
OncoAlert and ecancer weekly roundup for August 30 - September 5 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for August 30 - September 5 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
7 Sep 2020
OncoAlert and ecancer weekly roundup for August 24-29 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for August 24-29 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
1 Sep 2020
OncoAlert and ecancer weekly roundup for August 17-23 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for August 17-23 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
24 Aug 2020
OncoAlert and ecancer weekly roundup for August 1-8 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for August 1-8 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Aug 2020
PARP inhibitors and prostate cancer: A new era of precision medicine
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
PARP inhibitors and prostate cancer: A new era of precision medicine ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
4 Aug 2020
Oncology pharmacist perspective on PARP inhibitors for castration-resistant pros...
Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA
Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer ( Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA )
27 Jul 2020
The role of PARP-2 in inhibiting prostate cancer
Prof Li Jia - Harvard Medical School, Boston, USA
The role of PARP-2 in inhibiting prostate cancer ( Prof Li Jia - Harvard Medical School, Boston, USA )
27 Jul 2020
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advan...
Prof Scott Tykodi - University of Washington, Seattle, USA
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma ( Prof Scott Tykodi - University of Washington, Seattle, USA )
14 Jul 2020
Association of gene expression with clinical outcomes in RCC patients treated wi...
Prof Scott Tykodi - University of Washington, Seattle, USA
Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab ( Prof Scott Tykodi - University of Washington, Seattle, USA )
14 Jul 2020